PDCD1 and hepatocellular carcinoma: In a fecal metagenomics study, Zheng et al. reported that four Lactobacillus species were most abundant in the anti-PD-1 therapy response group; these data illustrated the characteristic profile of the gut microbiome as a novel predictive index of early outcomes in HCC patients receiving anti-PD-1 [101].